Jaguar Health Slides 13% to 52-Week Low as Pediatric Trial Advances
JAGX is trading near its 52-week low of $0.31 (4.6% above the low) on elevated volume (2.3× avg).
Summary
Jaguar Health shares fell 13.65% to $0.31, a new 52-week low, after the company announced that all randomized pediatric MVID patients in its pivotal trial have entered the single-blind extension phase. The Data Monitoring Committee authorized continuation, and the company reiterated a mid-2027 NDA submission target. The market reaction likely reflects the extended timeline and ongoing dilution concerns from the $40M equity line and recent S-1 filings. With only $3.8M in cash and a going concern warning, the stock remains highly speculative. The next major catalyst is the NDA filing, still roughly nine months away.
At the time of this announcement, JAGX was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.31 to $85.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.